분변잠혈 검사 시장 세계 시장 규모는 2024년 14억 2,690만 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 21억 4,220만 달러에 이르렀으며, 2025년부터 2033년까지 4.15%의 성장률(CAGR)을 나타낼 것으로 예측했습니다. 대장암의 유병률 상승, 비침습적 검사 기술의 현저한 진보, 인지도의 향상과 스크리닝 프로그램, 암의 조기 발견과 예방을 위한 정부의 이니셔티브의 고조, 인구의 고령화 등이 시장 성장을 가속하는 주요 요인입니다.
분변잠혈검사(FOBT)는 대변이나 대변에 숨어 있는 혈액을 검출하는 비침습적인 검사법입니다. 카드와 물로 씻어낼 수 있는 시약 패드 또는 조직을 사용하여 샘플을 채취하여 수행됩니다. 이 샘플은 검사를 위해 실험실로 보내져 치질, 게실증, 궤양, 대장염, 양성 종양, 대장 폴립 및 암과 같은 위장관에서 출혈을 일으키는 질병을 진단하는 데 사용됩니다. 현재, 조기 스크리닝에 대한 의식 증가가 분변잠혈 검사의 채용을 촉진하고 있습니다. 신속한 의료 판단을 가능하게 하고, 효과적인 헬스케어를 제공해, 생활의 질의 향상과 사망률의 저하로 이어지기 때문입니다.
POC(Point of Care) 진단(POCD) 지향 증가와 함께, 환자의 체감과 건강 결과를 개선하기 위한 통합 의료 서비스에 대한 주목이 증가하고 있는 것은 시장 성장을 자극하는 주요 요인 중 하나입니다. 이와는 별도로 노년 인구가 증가하고 있는 것도 나이가 들어감에 따라 질병에 걸릴 위험이 높아지면서 시장 성장을 가속화하고 있습니다. 그 결과, 다양한 국가의 행정기관이 노인을 위한 FOBT 스크리닝 프로그램을 실시했습니다. 또한, 낮은 침습(MI) 절차의 보급이 시장 성장에 기여하고 있습니다. 이 외에도 면역화학적 분변잠혈 검사(iFOBT 또는 FIT)는 사용하기 쉽고 암과 진행 선종에 대한 임상적 감도가 높기 때문에 인기를 끌고 있습니다. FOBT 장비는 온라인 소매점에서 쉽게 사용할 수 있기 때문에 향후 몇 년 동안 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 분변잠혈검사 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 검사 유형별
- 과이악 FOB편 검사
- 면역 FOB 응집 시험
- 래터럴 플로우 면역 FOB 검사
- 면역 FOB ELISA 검사
제7장 시장 내역 : 최종 용도별
제8장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 바이어 협상력
- 공급자의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Beckman Coulter Inc.(Danaher Corporation)
- Biohit Oyj
- EDP Biotech Corporation
- Eiken Chemical Co. Ltd.
- Epigenomics AG
- Quest Diagnostics Incorporated
- Quidel Corporation
- Randox Laboratories Ltd.
KTH
The global fecal occult testing market size reached USD 1,426.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,142.2 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033. The rising prevalence of colorectal cancer, significant advancements in non-invasive testing technologies, increasing awareness and screening programs, growing government initiatives for early cancer detection and prevention, and rising aging populations are some of the major factors propelling the market growth.
A fecal occult blood test (FOBT) is a noninvasive procedure used to detect hidden blood in the feces or stool. It is performed by collecting samples using cards and flushable reagent pads or tissues. These samples are sent to the laboratory for testing and are used to diagnose conditions such as hemorrhoids, diverticulosis, ulcers, colitis, benign tumors and colon polyps or cancer, which cause bleeding in the digestive tract. At present, the growing awareness about early screening is promoting the adoption of fecal occult testing, as it enables quick medical decisions, provides effective healthcare, and leads to improved quality of life and the reduced mortality rate.
The rising focus on integrated health services for improved patient experience and health outcomes, in confluence with the increasing inclination towards point-of-care diagnostics (POCD), represents one of the key factors stimulating the market growth. Apart from this, the rising geriatric population is accelerating the growth of the market as the risk of contracting diseases increases with age. As a result, governing agencies of various countries are implementing several FOBT screening programs for older adults. Furthermore, the widespread adoption of minimally invasive (MI) procedures is contributing to the growth of the market. Besides this, immunochemical fecal occult blood tests (iFOBTs or FITs) are gaining traction as they are easy to use and clinically more sensitive to cancers and advanced adenomas. The easy availability of FOBT devices at online retail stores is anticipated to create a positive impact on the market growth in the upcoming years.
Fecal Occult Testing Market Segmentation:
Breakup by Test Type:
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Breakup by End User:
Hospitals
Clinical Diagnostic Laboratories
Physician Office Laboratories
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Biohit Oyj, EDP Biotech Corporation, Eiken Chemical Co. Ltd., Epigenomics AG, Quest Diagnostics Incorporated, Quidel Corporation and Randox Laboratories Ltd.
Key Questions Answered in This Report:
- How has the global fecal occult testing market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global fecal occult testing market?
- What is the impact of each driver, restraint, and opportunity on the global fecal occult testing market?
- What are the key regional markets?
- Which countries represent the most attractive fecal occult testing market?
- What is the breakup of the market based on the test type?
- Which is the most attractive test type in the fecal occult testing market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the fecal occult testing market?
- What is the competitive structure of the market?
- Who are the key players/companies in the global fecal occult testing market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Fecal Occult Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Test Type
- 6.1 Guaiac FOB Stool Test
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Immuno-FOB Agglutination Test
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Lateral Flow Immuno-FOB Test
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Immuno-FOB ELISA Test
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by End User
- 7.1 Hospitals
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Clinical Diagnostic Laboratories
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Physician Office Laboratories
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Beckman Coulter Inc. (Danaher Corporation)
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Biohit Oyj
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.4 EDP Biotech Corporation
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 Eiken Chemical Co. Ltd.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 Epigenomics AG
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Quest Diagnostics Incorporated
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Quidel Corporation
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Randox Laboratories Ltd.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
